Johnson & Johnson price target raised to $240 from $230 at RBC Capital

RBC Capital raised the firm’s price target on Johnson & Johnson to $240 from $230 and keeps an Outperform rating on the shares as part of a broader research note previewing 2026 for Medical Supplies & Devices. The firm anticipates a year of positive momentum as sector fundamentals are solidly intact driven by the aging demographics, growing global healthcare access, and differentiated innovation, the analyst tells investors in a research note. For the company, RBC notes that JNJ appears poised to be a top-tier grower in MedTech with its strategy around “portfolio shifting” and “focused innovation” to participate in higher-growth end-markets.